The role of apatinib combined with chemotherapy in improving quality of life and levels of inflammatory cytokines of patients with advanced breast cancer

摘要

Objective: To explore the role of apatinib combined with chemotherapy in improving quality of life and levels of inflammatory cytokines of patients with advanced breast cancer. Methods: A total of 76 patients with advanced breast cancer admitted to our hospital were enrolled as research objects, and randomly divided into a research group (38 patients) and a control group (38 patients). The research group was treated with apatinib combined with chemotherapy, while the control group was administrated with apatinib alone. The two groups were observed in efficacy and incidence of adverse reactions after treatment, and the levels of their serum tumor markers including carcino-embryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 153 (CA153) were determined using chemiluminescence immunoassay before and after treatment; the serum concentrations of their inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factorF-alpha (TNF-alpha) were detected using enzyme-linked immuno sorbent assay (ELISA) before and after treatment, and their life quality score before and after treatment was recorded using the functional assessment of cancer therapy-breast (FACT-B) scale. Results: After treatment, the research group showed significantly lower serum IL-6 and TNF-alpha concentrations, serum tumor marker levels, incidence of adverse reactions, and significantly higher total effective rate and life quality score than the control group (all P<0.05), and the research group showed no significant difference with the control group in 3-year overall survival rate (P>0.05). Conclusion: Apatinib combined with chemotherapy is better than the single use of apatinib in the treatment of advanced breast cancer. It can better inhibit the growth of tumors, and the quality of life after treatment is significantly increased. It also reduces the incidence of adverse reactions after treatment by inhibiting the expression of IL-6 and TNF-alpha.